| Patent Number |
Title Of Patent |
Date Issued |
| 6541450 |
Parathyroid hormone analogues for the treatment of osteoporosis |
April 1, 2003 |
| This invention describes analogues of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailability. The peptides described are derivatives of hPTH-(1-31) which are cyclized for example, by formation of lactams between either Glu.sup.22 and |
| 6316410 |
Parathyroid hormone analogues for the treatment of osteoporosis |
November 13, 2001 |
| The invention disclosed relates to analogues of human parathyroid hormoneh(PTH) which have increased activities in bone restoration, and increased bioavailablities. The analogues described are either single cyclic (1-28) or (1-29) analogues, or double cyclic (1-28) to (1-31) analogue |
| 6110892 |
Parathyroid hormone analogues for the treatment of osteoporosis |
August 29, 2000 |
| This invention describes analogues of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailabilities. The peptides described are derivatives of hPTH-(1-31) which are cyclized for example, by formation of lactams between either Glu.sup.22 an |
| 5955425 |
Parathyroid hormone analogues for the treatment of osteoporosis |
September 21, 1999 |
| This invention describes analogs of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailabilities. The peptides described are derivatives of hPTH-(1-31) which have lactams formed for example, between either Glu.sup.22 and Lys.sup.26 or Lys |
| 5556940 |
Parathyroid hormone analogues for the treatment of osteoporosis |
September 17, 1996 |
| Certain analogues of human parathyroid hormone (hPTH) have been found to be effective for the treatment of osteoporosis, while showing decreased side effects. Analogues showing this effect include all sequences from hPTH-(1-28)-NH.sub.2 to hPTH-(1-31)-NH.sub.2 and all sequences from |
| 5378815 |
Process for indirect targeted immunocytolysis |
January 3, 1995 |
| A process is disclosed for treating cancer by the process of indirect targeted immunocytolysis, which comprises conjugating an immunogenic sensitizing agent to a targeting agent which is capable of binding to aberrant cells, such as cancer cells in a human or animal host. The conjuga |
